Abstract-One of the challenges in developing sustainedrelease local drug delivery systems is the limited treatment volume that can be achieved. In this work, we examine the effectiveness of using low frequency, high intensity ultrasound to promote the spatial penetration of drug molecules away from the implant/injection site boundary upon release from injectable, phase inverting poly(lactic acid-co-glycolic acid) (PLGA) implants. Fluorescein-loaded PLGA solutions were injected into poly(acrylamide) phantoms, and the constructs were treated daily for 14 days with ultrasound at 2.2 W/cm 2 for 10 min. The 2D distribution of fluorescein within the phantoms was quantified using fluorescence imaging. Implants receiving ultrasound irradiation showed a 1.7-5.6 fold increase (p < 0.05) in fluorescence intensity and penetration distance, with the maximum increase observed 5 days post-implantation. However, this evidence was not seen when the same experiment was also carried out in phosphate buffer saline (pH 7.4). Results suggest an active role of ultrasound in local molecular transport in the phantom. An increase of fluorescein release and penetration depth in phantoms can be accomplished through brief application of ultrasound. This simple technique offers an opportunity to eventually enhance the therapeutic efficacy and broaden the application of local drug delivery systems.
INTRODUCTION
Drug delivery systems are an essential component of successful pharmaceutical development. They are particularly important in cancer therapy where the therapeutic index of the drug is often quite small and the stability of biologic agents is limited. 24, 40 In situ forming implants (ISFI) used for local drug delivery directly into the tissue of interest (e.g., a tumor) are an attractive alternative route to oral and intravenous administration. 36 Through a minimally invasive injection procedure using a small-gauge needle, ISFI can deliver effectively high dosages of drugs directly to the target site, minimize systemic side effects, and help increase the patient compliance through decreased frequency of administration. 2 PLGA, poly(lactic acidco-glycolic acid) polymers have been used as a foundation for many ISFI formulations and other Food and Drug Administration (FDA) approved products due to their biocompatibility and biodegradability. 2 Injectable implants using PLGA were developed over 25 years ago, but have not gained broad clinical acceptance. 2 This is especially true for applications where the desired site of action is localized in the immediate vicinity of the implants, such as in the case of intratumoral chemotherapy. In contrast, in applications where long term systemic drug activity is desirable, ISFI have been utilized more frequently. 25 Limited use of ISFIs in site-specific applications in cancer can be attributed to numerous factors, but one significant issue is the inadequate distribution of the drug locally upon release from the implants. 38 Prior studies report penetration of released doxorubicin in liver tissue in range of 2-3 mm from the implant boundary. 37 Distribution of SN-38 released from SN-38-loaded depots was 6 mm from the boundary after 20 days post-implantation in the brain. 18 To address this challenge with ISFI, here we demonstrate a unique approach to increase local penetration of drug released locally from ISFI using ultrasound.
Ultrasound is a common diagnostic tool. In addition to common clinical applications, ultrasound has also been used to facilitate drug release on demand in transdermal drug delivery systems 20 and has been shown to improve the penetration of nanoscale particles though epithelial cells or other physical barriers. 11, 32, 33 In this process, typically it is the mechanical and thermal effects which are associated with an increase in penetration, perfusion or release of the drug. 6, 33 Recently, ultrasound was also used to control release of insulin from a gel-like network system consisting of alginate-coated nanoparticles and chitosancoated nanoparticles. During treatment with focused ultrasound, the network was deformed and promoted insulin release. 4 Low-intensity focused ultrasound is also used in number of applications to destroy gasfilled microbubbles, which leads to sonoporation and improved drug delivery parameters such as drug penetration or cellular uptake. 6 Building upon this body of research, our current work examines the feasibility of using ultrasound to enhance drug molecule transport from in situ forming implants and throughout the surrounding injection site, here tissue mimicking poly(acrylamide) gel phantoms.
MATERIALS AND METHODS

Chemicals
Sodium fluorescein and N-methyl-2-pyrrolidinone (NMP) were obtained from Sigma-Aldrich (St. Louis, MO). Poly(DL-lactic-co-glycolic) acid (PLGA) with a carboxylic acid end group, 50:50 DLG 4.5A, inherent viscosity (0.4-0.5 dL/g) was obtained from Lakeshore Biomaterials (Birmingham, AL). Acrylamide, bis-acrylamide, ammonium persulfate (APS), and N,N, N¢,N¢-tetramethylethylenediamine (TEMED) were obtained from Fisher Scientific (Waltham, MA).
Phantom Preparation and In Vitro Distribution Study
A tissue-mimicking hydrogel phantom (2 kPa elastic modulus) was prepared by free-radical polymerization of acrylamide [6.45% (w/v)] and bisacrylamide [0.095% (w/ v)] using TEMED and APS. 8 The phantoms (17 mL) were polymerized within a 6-well plate and kept in PBS solution for 5 days before implantation. The formulation of implant solutions was described in the previous work. 8, 34 Briefly, fluorescein was dissolved in NMP and incubated at 37°C for 1 h. PLGA was then added into the solution and left in the incubator with circulation mixture at 37°C overnight. Herein, the mass ratio of PLGA:NMP:fluorescein was fixed at 39:60:1. Implants (~45 lL) were directly injected through 21G syringe needle into phantoms. To prevent the drug release through the needle track, the needle was held in place by a clamp at the injection site for 5 min before removal. Phantoms containing implants were then kept in 60 mL of PBS, and incubated at 37°C with an orbital shaking at 80 rpm. A commercially available physical therapy ultrasound unit (Omnisound Ò 3000, Accelerated Care Plus Corp., Reno, NV) equipped with two collimating transducers was used to expose ultrasound wave to samples. 3 h after the implant was injected into the phantom, ultrasound was applied at either 0.7 or 2.2 W/ cm 2 intensity for 10 min (33% duty cycle, pulse duration 2 ms, 3 MHz, using a 4.0 cm 2 surface area probe). The application of ultrasound was repeated daily for the duration of the study. The setup is shown in Fig. 1 . To study effect of hyperthermia, phantoms with implants were incubated in a water bath at 42°C for 10 min in lieu of ultrasound application. To measure temperature, a thermocouple probe (HH-21A, OMEGA Ò ) was inserted into the phantom proximal to the implant. The constructs were evaluated daily using a fluorescence imaging system (CRI Maestro, Caliper Life Science) with a blue excitation/emission filter (435-480 nm/515 nm) and an exposure time of 10 ms. Fluorescence intensity was analyzed using ImageJ (National Institutes of Health) with the ''Radial Profile'' plugin.
Preparation of Implants and Measurement of In Vitro Release
To investigate in vitro release in PBS, the polymer solution (~45 lL) was injected into 30 mL of PBS to form an implant and placed at 37°C and 80 rpm. Ultrasound at 2.2 W/cm 2 with the same parameters as above was applied daily to each implant for 10 min. The distance between the transducer and implant was fixed at 1.5 cm. Implants were localized using a cap of a 15 mL centrifuge tube to reduce implant movement away from the sonication site during application of the ultrasound treatment. The same volume of PBS was replaced after ultrasound application. At the predetermined time, the amount of released fluorescein was determined via microplate reader (Tecan Ltd, Infinite 200 series) at an excitation wavelength of 485 nm and an emission wavelength of 525 nm.
In vitro release was also measured in the phantoms. Here, fluorescein-loaded implants (~45 lL) were injected into phantoms as for the distribution experiments. At predetermined time points (6 h, 1, 3, 5, 7, 10, and 14 days), implants were removed from the phantoms and dissolved in 2 M NaOH to measure the amount of fluorescein that was remaining in the removed implants. The amount of released fluorescein was calculated by comparing the residual fluorescein remaining in each implant to the initial loading amount at t = 0.
Degradation Study
Implants were prepared as above, injected either into phantoms or into PBS and treated as described above using 2.2 W/cm 2 and the 4.0 cm 2 surface area probe. Implants were collected after 3, 7, and 14 days post-injection, washed with distilled water and freeze-dried. Implants were then dissolved in tetrahydrofuran (THF) to a concentration of 10 mg/mL followed by filtration (0.2 lm PTFE syringe filter). Molecular weight of the polymers was analyzed by GPC (EcoSEC GPC system with RI and UV detector: wavelength at 254 nm) and TSKgel SuperHM-M column (4.6 mm 9 15 cm, 4 lm) at a flow rate of 0.35 mL/min, 40°C.
Statistical Analysis
All data were expressed as mean ± SD. All studies were carried out at least in triplicate. Significant differences within data were calculated and evaluated using an unpaired t test. p value (<0.05) was considered as statistically significant.
RESULTS
Fluorescein Distribution in Phantoms
The distribution of fluorescein in poly(acrylamide) phantoms is shown in Fig. 2 . The overall implant mass of control group, water bath group, and treated groups at 0.7, 2.2 W/cm 2 were 48.8 ± 5.4, 47.3 ± 3.0, 52.9 ± 2.2, and 49.1 ± 1.3 mg, respectively. Upon qualitative examination, it can be seen that the fluorescein distribution around implants that received treatment at 2.2 W/cm 2 was greater than the no-ultrasound control from day 2 to day 10 after implantation. Treatment with ultrasound at 0.7 W/cm 2 or in the 42°C water bath did not appear to have any effect on the fluorescein distribution. In addition, only minor differences were noted between all groups during the first 2 days after injection ( Supplementary Fig. S1 ). Likewise, distribution of free unencapsulated fluorescein solution was not affected by ultrasound application. This experiment was carried out by injection of fluorescein solution (NMP) into the phantom and monitored by the same procedures as implants for 3 days (Supplementary Fig. S2 ).
The mean radial fluorescence intensity profiles plotted from the center of each implant are shown in Fig. 3 . Signal intensity in the group treated with ultrasound at 2.2 W/cm 2 was significantly higher than control during 3-10 days (Figs. 3b-3e ) post-implantation. At the implant-phantom boundary (~0.2 cm from center of implants), fluorescein intensities from treated group at 3, 5, 7, and 10 days post-implantation were 2.4, 6.0, 2.0, and 1.7-fold greater (p < 0.05) than control group, respectively, whereas group treated with 0.7 W/cm 2 had the same distribution as control. Likewise, at a distance of 1 cm from implant center, the intensities were 1.7, 5.6, 3.0, and 1.8-fold greater than control at 3, 5, 7, and 10 days post-implantation. Area under the curve (AUC) calculations are shown in Fig. 4 . The AUC of the implants receiving 2.2 W/cm 2 was significantly (p < 0.05) different at 3, 5, 7, and 10 days post-implantation from both the control group receiving no ultrasound and the group heated in FIGURE 1. Schematic of enhancement of fluorescein distribution via therapeutic ultrasound using a poly(acrylamide) gel phantom to mimick tissue. The therapeutic ultrasound was daily exposed from the top of the phantom for 10 min at 3 MHz and 33% duty factor. the 42°C water bath. In addition, change in temperature after ultrasound treatment was recorded to be near 5°C, Supplementary Fig. S3 . The temperature inside the phantoms from ultrasound treated group and the phantoms that were incubated in 42°C water bath increased at the same rate. Importantly a 10 min, 5 degree temperature change was not expected to have a major effect on normal tissue if this method were applied clinically. 39 
Fluorescein Release
Implants injected into PBS had a mass of 41.0 ± 0.6 mg and 42.6 ± 1.9 mg for control and ultrasound-treated groups, respectively. Average cumulative release of fluorescein was shown in Fig. 5a . The initial burst was approximately 41% in the first 24 h in the control group compared to 50% in the ultrasound-treated group. However, no significant differences were observed including with application of the therapeutic ultrasound. Implants injected into the phantoms had a mass of 47.8 ± 11.1 and 51.0 ± 6.2 mg for control and ultrasound-treated groups, respectively. Using the same criteria release kinetics, 8, 28, 35 the ultrasound-treated group showed an increase in release during the diffusion phase (>72 h) compared with the control, Fig. 5b . This is consistent with the increase in drug distribution on days 3, 5, 7 and 10.
Polymer Degradation
The molecular weight of PLGA of both control and treatment groups was found to be approximately 56.4 ± 5.2%, 48.4 ± 4.5%, and 22.3 ± 1.2% of the original value at 3, 7, and 14 days post-injection in PBS, Fig. 6 . In the poly(acrylamide) phantom, a slight but significant difference at 7 days post-injection was seen between the treated and control groups (23.7 ± 1.2 vs. 28.4 ± 2.4%). PLGA implants undergo bulk erosion. 41 The implants upon contact with water undergo rapid ester bond cleavage throughout the FIGURE 2. Effect of ultrasound on fluorescein distribution in poly(acrylamide) gel phantoms. The phantoms were randomly classified into three groups including control, incubating in water bath, and ultrasound treated group. For incubating in water bath group, phantoms were incubated daily in water bath at 42°C for 10 min. Treated samples were exposed to therapeutic ultrasound daily for 10 min at either 0.7 or 2.2 W/cm 2 , 3 MHz, and 33% duty factor.
system. Increase of acidic byproducts especially in the phantoms likely resulted in the rapid MW loss as shown in Fig. 6 . This degradation was higher than that of PLGA implants without phantoms where the PBS was frequently replaced. The local pH of the implants in the phantoms was lower (data not shown) and generated more autocatalysis degradation rate. The GPC chromatograms of all implants were presented in Supplementary Fig. S4 . For the 42°C group, phantoms were incubated in 42°C water bath for 10 min. Treated samples were exposed to therapeutic ultrasound daily for 10 min at either 0.7 or 2.2 W/cm 2 , 3 MHz, and 33% duty factor. The dashed black line represented the boundary of implants. Each value represents the mean 6 SD (control group, n 5 6; other groups, n 5 3). Asterisk designates significant differences from the control group (p < 0.05).
DISCUSSION
The use of polymeric implants for drug delivery has been extensively investigated with non-degradable polymers such as ethylene-vinyl alcohol and biodegradable polymer like PLGA. 18, 21, 36 However, regardless of the polymer matrix, overall local delivery of drugs or compounds has been limited by passive diffusion leading to low penetration and distribution. To overcome these challenges, ultrasound can be enlisted as a safe external force to facilitate drug release and distribution in vivo. 11, 16, 32, 33 Several prior studies have examined the use of ultrasound to enhance drug release from polymer implants. 5, 6, 22 In contrast to the current study, these studies included gas bubbles or generation of heat, which were able to drive drug release via inertial cavitation and/or mild hyperthermia. Ultrasound exposure has also been shown to significantly increase degradation rate of the polymer matrix, especially polyanhydrides, or reform the structure of the polymer such as cross-link hydrogel or shape memory polymers. 4, 9, [12] [13] [14] 21 However, while the use of ultrasound for active, on demand, delivery of drugs has been under extensive investigation, 1, 11, 30, 33 its application in increasing drug distribution upon re-FIGURE 4. Area under the curve (AUC) calculated form distribution profiles (mean 6 SD). For the water bath group (42°C), phantoms were incubated in a water bath for 10 min. Treated samples were treated with daily therapeutic ultrasound for 10 min at either 0.7 or 2.2 W/cm 2 , 3 MHz, and 33% duty factor Each value represents the mean 6 SD (control group, n 5 6; other groups, n 5 3). Asterisk designates significant differences from the control group (p < 0.05). lease from in situ forming polymer implants has not been investigated.
Compared to other techniques such as magnetic nanoparticles, 7 ultrasound is less costly, simpler and does not depend on a high local concentration of nanoparticles to achieve the desired effect. Different carriers and strategies capitalizing on the mechanical forces of ultrasound for drug delivery to tumors have been studied. These strategies are either applied to various existing drug loaded nanoparticles such as liposomes 10, 29 or use ultrasound-visible microbubbles in combination with therapeutics. 19, 31 Applying therapeutic ultrasound to in situ forming implants could become an alternative method to enhance release and distribution of agents without any additional gas bubbles. Herein, fluorescein-loaded PLGA implants were prepared in 2 kPa elastic modulus phantoms. This phantom had constant mechanical property for 14 days. The hydrogel phantom provides a physical structure with high water content and tunable biologically-relevant mechanical properties. 8, 27 In this study, we investigated the application of ultrasound from a single transducer applied at a low (0.7 W/m 2 ) and high (2.2 W/cm 2 ) intensity on ISFIs and compared them to untreated controls. Overall, only the higher intensity ultrasound was found to significantly increase the rate of fluorescein release, polymer degradation and to effectively and significantly increase the drug penetration distance through hydrogel phantoms. In contrast, ultrasound application to implants formed in PBS had no perceived effect when the distance between the transducer and the implant was fixed at around 1.5 cm. Likewise, ultrasound applied to fluorescein solution (without entrapment in a polymer implant) had no effect on distribution at either intensity.
Overall, the total amount of fluorescein released in the phantoms was greater for implants treated with ultrasound. This effect was noted as early as 1 day after injection, and the increase was significant at 7 and 10 days. Increase in fluorescein release was not observed in PBS. Especially between 1 to 9 days postimplantation, fluorescein release in PBS (which was in the diffusion phase) was found to be 1-2% per day. In contrast, for PLGA implants in the degradation phase (9 days post-implantation), the rate of fluorescein release was higher, which is consistent with prior reports. 35 A slightly faster degradation rate was noted for the ultrasound group at 3, 7 and 14 days in phantoms. The difference was significant after day 7 but no longer at day 14. Since the ester bond of PLGA was cleaved by water, the accumulation of lactic acid products could increase in the local pH (autocatalysis). For implants in the phantoms, a localized accumulation of the acidic byproducts could lead to increased PLGA degradation. 41 It should be noted that implant from both groups were almost completely degraded after 21 days (data not shown). Overall, however, the differences were minor and thus are not thought to have contributed to the sustained increase in drug penetration.
When applied in the context of nanoparticles and/or bubbles, the mechanism of US-enhanced delivery is likely to be a combination of three factors: cavitation, acoustic streaming and hyperthermia, all resulting from interactions of particles and tissues with the ultrasound waves. 17, 33 These factors are used to increase permeability of vessels, cell walls, and the blood brain barrier, and can also be used to drive drug release from particles. The acoustic radiation force resulting from the longitudinal pressure waves moving through tissue can also be used to move particles along the same direction. This has been used to enhance particle interaction with targets, and alter the particle distribution within target tissue. 17, 32 The same acoustic radiation force is also the foundation of shear wave generation used for elastography imaging. 3, 23 Shear wave elastography is used clinically to measure tissue stiffness in liver fibrosis and cancer. 3, 15, 26 When examining our data, since hyperthermia had no effect on either drug release or distribution as shown in Figs. 2, 3 and 4 , it is possible that, combined with increased diffusion, complementary mechanical effects propagating through the viscoelastic phantoms lead to the observed increase in the volume of distribution. It is important to note, however, that the hyperthermia via therapeutic ultrasound likely radiated from the implant outward, while that from the water bath radiated from the outside toward the implant. This could contribute to distinct effects on the implant itself and drug distribution within the implants. In addition, while hyperthermia may not be the driving force in this system, in future clinical applications in cancer therapy, the mild hyperthermia could certainly lead to synergistic therapeutic effects when combined with the local chemotherapy delivery.
As an alternative or additional mechanism for the observed effects, we hypothesize that it could be the implant itself, and its progressive hardening (resulting from solvent exchange and polymer precipitation) that acts as a seed for generation of these effects. Full implant solidification has been shown to take up to 3 days, 34 and therefore may explain why the enhancement in drug penetration was not observed at the initial time points. It is also important to note that the release of fluorescein from the implants increased with the application of the higher intensity ultrasound. Additional in depth experiments are necessary to decouple these effects and establish the specific underlying mechanism driving these observations. This study still has several limitations. Foremost are the limited acoustic parameters which could be manipulated with the available ultrasound equipment. In depth parameter optimization with a more robust acoustic setup and focused transducers could yield even greater enhancement and lead to understanding of the underlying mechanisms. Another limitation was the use of fluorescein as a mock drug. It should be noted that the previous study described the similarity between fluorescein and doxorubicin in terms of release profile, release kinetics in both in vitro and in vivo. 35 However, because implant behavior differs depending on the formulation, drug loading extent, polymer molecular weight and the like, additional research is required to understand the contribution of each of these on the observed acoustic-enhancement effect. Accordingly, the experiments here delineate only relative differences between the treatment groups and they cannot be used to accurately predict in vivo behavior. Additional experiments must be conducted to establish this strategy in vivo in an animal model, where the complexities of the tumor environment will play a significant role on the outcome.
In conclusion, the study demonstrates that a straightforward ultrasound protocol can be used to increase the release rate and spatial distribution of fluorescein released from in situ forming PLGA implants. Although the mechanism behind these observations is not entirely understood, we pose that coupled with increased local drug release, the acoustic radiation force interacting with the PLGA implants could result in increased drug release and penetration in the viscoelastic phantoms. This strategy could be eventually utilized to increase the treatment volume of ISFIs in tumors and lead to improved outcomes in treatment of various malignancies where local tumor control is desired.
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